Ipilimumab (Yervoy)

Ipilimumab is an immunotherapy drug that helps the immune system attack cancer by blocking a protein on T cells called CTLA-4, which normally acts as a brake on immune activity. For mesothelioma, it is given together with nivolumab (Opdivo) as a first-line treatment for unresectable pleural mesothelioma. It is delivered by IV infusion in an oncology clinic.

Origin

Developed by Medarex and later Bristol-Myers Squibb, ipilimumab was the first CTLA-4 inhibitor approved by the FDA (in 2011 for melanoma). The name follows World Health Organization naming rules for monoclonal antibodies: the "-mab" suffix identifies it as a monoclonal antibody. In October 2020, the FDA approved nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma, the first new systemic therapy approved for this disease in over 15 years.

Significance in Asbestos Context

For patients with pleural mesothelioma that cannot be removed by surgery, the nivolumab–ipilimumab combination is now a standard first-line option, based on the CheckMate 743 trial, which showed improved overall survival compared to traditional chemotherapy (pemetrexed plus cisplatin or carboplatin). The benefit was particularly notable for patients with non-epithelioid (sarcomatoid or biphasic) histology, who historically respond poorly to chemotherapy. Because immunotherapy can cause distinctive immune-related side effects affecting the colon, liver, lungs, skin, and endocrine glands, treatment requires close monitoring. Documentation of this treatment (including infusion records, side effects, and response on imaging) becomes part of the medical record that supports both your medical care and the damages portion of any asbestos claim.

Example Sentence

After her biphasic pleural mesothelioma was deemed inoperable, her oncologist started her on ipilimumab (Yervoy) combined with nivolumab (Opdivo) as first-line therapy.

Related Terms

Nivolumab (Opdivo), Immunotherapy, Checkpoint Inhibitor, Malignant Pleural Mesothelioma, CheckMate 743, CTLA-4

Notes

• Ask your oncologist whether the nivolumab + ipilimumab regimen is appropriate for you, especially if your tumor is sarcomatoid or biphasic; histology type strongly influences which first-line therapy is recommended.
• Watch for immune-related side effects, diarrhea, severe fatigue, rash, shortness of breath, or new endocrine symptoms (thyroid, adrenal), and report them immediately, as early steroid treatment can prevent serious complications.
• Keep copies of all infusion records, imaging reports, and side-effect documentation; these establish the cost, burden, and impact of treatment for both insurance appeals and legal damages calculations.
• Confirm insurance authorization in advance, as ipilimumab is expensive; manufacturer patient-assistance programs (Bristol-Myers Squibb Access Support) may help with copays.